Tubal Ligation is an operation to tie the fallopian tubes closed. This procedure prevents pregnancy by blocking the passage of eggs from the ovaries to the uterus.
The early morning highlights from the major news organizations examine today's deadline for enrolling for health insurance that would begin Jan. 1, as well as a variety of other health law stories and several articles on mental health issues:
A revised Medicaid sterilization policy that removes logistical barriers, including a mandatory 30-day waiting period, could potentially honor women's reproductive decisions, reduce the number of unintended pregnancies and save $215 million in public health costs each year, according to researchers at the University of Pittsburgh School of Medicine.
A novel study shows women who undergo surgical treatment for endometriosis have a lower risk of developing ovarian cancer. According to results published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, hormonal treatments for endometriosis did not lower ovarian cancer risk.
Roughly two in five women in the United States do not use any form of birth control and many underestimate their risk for pregnancy, according to a recent survey about contraceptive practices in the United States.
Give him points for cleverness. President Obama's birth control "accommodation" was as politically successful as it was morally meaningless. It was nothing but an accounting trick that still forces Catholic (and other religious) institutions to provide medical insurance that guarantees free birth control, tubal ligation and morning-after abortifacients -; all of which violate church doctrine on the sanctity of life.
A recent first-of-its-kind survey of 1,006 mothers in the U.S. showed that more than 75 percent of women reported being done having children, but only 24 percent discussed this decision with their OB/GYNs.
Ovarian cancer is a rare but often deadly disease that can strike at any time in a woman's life. It affects one in 70 women and in the past was referred to as a silent killer, but researchers have found there are symptoms associated with ovarian cancer that can assist in early detection. Experts at Northwestern Memorial say the best defense is to make use of preventive methods, understand the risks and recognize potential warning signs of ovarian cancer.
Conceptus Inc., developer of the Essure procedure, the most effective non-surgical permanent birth control method available, today announced receipt of the CE mark for use of Transvaginal Ultrasound to confirm proper placement of Essure micro-inserts three months following the Essure procedure.
NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners. The company also announced the establishment of its corporate headquarters in Cambridge, Mass. where Charles Carignan, M.D., serves as president and chief executive officer.
Pro-Vas® – the new faster, less-invasive alternative to traditional vasectomy – was featured Thursday in millions of homes and doctors' offices across the nation on "The Doctors" TV show. This nationally syndicated show highlights significant advancements in the world of health and medicine.
Gynecologic oncologists with the Ovarian Cancer Research Program at Vancouver General Hospital (VGH) and the BC Cancer Agency have begun an important campaign that will reduce deaths from ovarian cancer.
PregLem, the Swiss specialty biopharmaceutical company focused on women's reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.
Conceptus, Inc., developer of the Essure procedure, the first proven non-surgical permanent birth control method available, today reported financial results for the three months ended June 30, 2010.
According to the recently released 2006-08 National Survey of Family Growth by the Center for Disease Control, one in four women choose permanent birth control. Conceptus, Inc. wants women to know that its Essure permanent birth control procedure has been gaining in popularity, and is a safe and effective solution used by hundreds of thousands of women worldwide.
Conceptus Inc., developer of the Essure(R) procedure, the first and proven non-surgical permanent birth control method, announced today that the third generation (ESS305) of the Essure procedure has received FDA-approval for an improved bilateral placement rate of 96.9%. Improvement in the hysteroscopic time of 9 minutes is an additional benefit.
Most women scheduled for gynecologic surgery to address noncancerous symptoms said in a recently published survey that they were not worried about the effects of the procedure on their sex lives.
Conceptus, Inc., developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the United Stated District Court, Northern District of California has denied Conceptus’ motion for a preliminary injunction prohibiting Hologic, Inc. from importing, using, selling or offering to sell the Adiana system in the United States.
Conceptus, Inc., developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the clinical success of the Essure® procedure will be highlighted at the 18th Annual Congress of the European Society for Gynaecological Endoscopy (ESGE) in Florence, Italy from October 28-31, 2009.
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the United Kingdom's National Institute for Health and Clinical Excellence (NICE), in its updated guidance for hysteroscopic sterilization, supports the use of Hologic's Adiana((R)) permanent contraception system.
Researchers from the Centers for Disease Control and Prevention (CDC) found that survival among women with ovarian cancer is influenced by age of menarche and total number of lifetime ovulatory cycles.